Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Harnessing intermittent systemic hypoxia-mimicry to enhance regeneration and functional recovery following peripheral nerve and spinal cord injuries
EF 2024-25
Résumé
Hypoxia-inducible factor 1 a (HIF1 a) increases O levels in hypoxic tissues and is up-regulated in the dorsal root ganglion after axonal injury, suggesting a role in functional recovery. Inhibiting negative regulators of HIF1 a accelerates axon regeneration, likely through macrophage-mediated pro-regenerative effects. Continuous treatment with dimethyloxalylglycine (DMOG), a hypoxia-mimetic drug, speeds up regeneration and functional recovery after peripheral nerve injury, enhances macrophage density and growth-supportive phenotypes, and induces prolonged angiogenesis. DMOG withdrawal causes vascular regression, macrophage reactivation, and regenerative marker expression (i.e., ATF3), suggesting intermittent treatment could further boost regeneration. We will study effects of intermittent DMOG on regenerating peripheral nerve and spinal cord pathways following sciatic nerve crush, C5-T1 dorsal root crush, and C8-T1 dorsal column injuries. Mice will receive DMOG or vehicle in a 3-day-on, 3-day-off cycle over 6, 12, 24, or 48 days. Sciatic nerve regeneration will be assessed by hind-paw skin innervation by CGRP- and PGP9.5-positive axons and VGLUT1-positive IA afferent staining. Function will be evaluated with nociceptive, grasping, and stretch reflexes. Dorsal root regeneration will be traced with wheat germ agglutinin and cholera toxin B fragment (CTB), and function will be assessed by nociceptive and grasping reflexes, and dorsal horn interneuron activity. Dorsal column regeneration will be evaluated with CTB tracing of ascending axons, and function will be determined via stepping errors and gait. DMOG and control results will be compared to assess regenerative and functional effects. We aim to improve recovery and quality of life for those with neuro-traumatic injuries.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529891
Name
Elford Hanna R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing intermittent systemic hypoxia-mimicry to enhance regeneration and functional recovery following peripheral nerve and spinal cord injuries
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Axons; Drug Testing; Hypoxia; Nervous System; Neuroscience; Regeneration; Regenerative Medicine; Sensory Neurobiology; Spinal Cord Injury; Treatment
Abstract
Hypoxia-inducible factor 1 a (HIF1 a) increases O levels in hypoxic tissues and is up-regulated in the dorsal root ganglion after axonal injury, suggesting a role in functional recovery. Inhibiting negative regulators of HIF1 a accelerates axon regeneration, likely through macrophage-mediated pro-regenerative effects. Continuous treatment with dimethyloxalylglycine (DMOG), a hypoxia-mimetic drug, speeds up regeneration and functional recovery after peripheral nerve injury, enhances macrophage density and growth-supportive phenotypes, and induces prolonged angiogenesis. DMOG withdrawal causes vascular regression, macrophage reactivation, and regenerative marker expression (i.e., ATF3), suggesting intermittent treatment could further boost regeneration. We will study effects of intermittent DMOG on regenerating peripheral nerve and spinal cord pathways following sciatic nerve crush, C5-T1 dorsal root crush, and C8-T1 dorsal column injuries. Mice will receive DMOG or vehicle in a 3-day-on, 3-day-off cycle over 6, 12, 24, or 48 days. Sciatic nerve regeneration will be assessed by hind-paw skin innervation by CGRP- and PGP9.5-positive axons and VGLUT1-positive IA afferent staining. Function will be evaluated with nociceptive, grasping, and stretch reflexes. Dorsal root regeneration will be traced with wheat germ agglutinin and cholera toxin B fragment (CTB), and function will be assessed by nociceptive and grasping reflexes, and dorsal horn interneuron activity. Dorsal column regeneration will be evaluated with CTB tracing of ascending axons, and function will be determined via stepping errors and gait. DMOG and control results will be compared to assess regenerative and functional effects. We aim to improve recovery and quality of life for those with neuro-traumatic injuries.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Elford, Hanna R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~